; (ii) impose higher cost-sharing with respect to such insulin than the cost-sharing that applied with respect to the certified insulin in the year in which the list price reduction certification was provided under section 5(b)(2)(A) of the Insulin Price Reduction Act ; (iii) impose any prior authorization requirements for coverage of the certified insulin that were not applied during the year in which the list price reduction certification was provided under such section 5(b)(2)(A); or (iv) establish a step therapy requirement for the certified insulin that was not applied during the year in which the list price reduction certification was provided under such section 5(b)(2)(A). (2) Definitions In this section: (A) Certified insulin The term certified insulin means, with respect to a year, insulin that has been certified under section 5(b) of the Insulin Price Reduction Act for the year. (B) Insulin The term insulin means any insulin product approved by the Food and Drug Administration to improve glycemic control in patients with diabetes mellitus. (C) List price The term list price has the meaning given the term wholesale acquisition cost in section 1847A(c)(6)(B). (D) Rebate The term rebate means any discount, price concession, or fee, other than the fee described in paragraph (1)(B), the terms of which are fixed at the time of the sale and disclosed, but which is not received at the time of the sale. . 4. Applicability of pre-list price reduction AMP to Medicaid minimum rebate amounts Section 1927(c) of the Social Security Act ( 42 U.S.C. 1396r–8(c) ) is amended— (1) in paragraph (1)(A), in the matter preceding clause (i), by inserting and paragraph (5) after paragraph (2) ; (2) in paragraph (3)(A), in the matter preceding clause (i), by inserting and paragraph (5) after subparagraph (C)